Movano Health announced that it commenced a blood pressure clinical trial with its new cuffless wrist wearable.
Pleasanton, California-based Movano designed its updated device to monitor pulse pressure waveforms. The study — expected to include at least 70 participants — is expected to finish in the second week of February. It utilizes Movano’s device in comparison with a hospital-grade blood pressure device.
Related: Median Technologies’ eyonis™ screening meets primary endpoint in RELIVE clinical trial
In addition to blood pressure, Movano developed the device to collect data on a number of other vital signs. Those include pulse rate, blood oxygen saturation (SpO2), respiration rate and ECG waveforms.
Movano said its latest study follows three clinical trials that took place in 2023 and 2024. Those studies used non-invasive devices to collect pulse pressure waveform data from more than 60 participants of varying gender, age, ethnicity and BMI. During each session, participants wore Movano’s wrist-worn device along with an FDA-cleared, hospital-grade vital signs monitor with cuffed blood pressure measurements.
In mid-2025, the company plans to execute an additional 100-150-person continuous blood pressure study using an arterial line. It expects results to help finalize the algorithm used in a potential FDA pivotal trial in the future.
“We have learned a great deal since our last clinical trial in November 2024 and have refined the use of our proprietary cuffless blood pressure wearable in order to extract higher fidelity data,” said Movano Health’s CTO and founder Michael Leabman. “I’m excited about the potential the enhanced design offers relative to our previous prototype as it represents a significant leap forward in cuffless blood pressure monitoring.”
